{"text": "TITLE:\n      Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer\nSUMMARY:\n      EGF104578 is two-part study (Pilot part/Randomized part).Pilot part is designed to find the\n      optimal (best) doses of lapatinib and paclitaxel when given together,Randomized part is\n      designed to evaluate the overall survival in patients receiving lapatinib and paclitaxel\n      compared to patients receiving only paclitaxel.\nELIGIBILITY CRITERIA:\n      Inclusion criteria:\n        Specific Information regarding warnings, precautions, contraindications, adverse events,\n        and other pertinent information on the investigational product that may impact subject\n        eligibility is provided in the Investigator's Brochure (IB) Pilot Part\n        Subjects eligible for enrollment in the Pilot Part of the study must meet all of the\n        following criteria:\n          -  Signed informed consent\n          -  Male or female; \u2265 20 years (at the time of giving consent)\n          -  Any histologically or cytologically confirmed gastric carcinoma independent of tumor\n             ErbB2 status\n          -  Subjects who have received one prior regimen for gastric carcinoma and developed\n             disease progression or recurrence. The regimen must have contained 5-fluoropyrimidine\n             and/or cisplatin\n          -  Left ventricular ejection fraction (LVEF) within institutional range of normal as\n             measured by echocardiogram (ECHO). Multigated acquisition (MUGA) scans will be\n             accepted in cases where an echocardiogram cannot be performed or is inconclusive\n             (LVEF of \u226550% required if normal range of LVEF is not provided by institution)\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1\n          -  Able to swallow and retain oral medication\n          -  Women and men with potential to have children must be willing to practice acceptable\n             methods of birth control during the study\n          -  Washout period from the prior last therapy as follows; Chemotherapy (except for\n             agents below) 4 weeks (I.V) Chemotherapy (except for agents below) 2 weeks (P.O)\n             Trastuzumab, Bevacizumab 4 weeks Mitomycin-C, nitrosourea 6 weeks Radiotherapy,\n             Immunotherapy, Biologic therapy and Surgery (except for minor surgical procedure) 2\n             weeks\n          -  Willing to complete all screening assessments as outlined in the protocol\n          -  Adequate organ function as defined in Table 2 Baseline Laboratory Values\n          -  Able to be hospitalized for PK analysis during cycle 1\n          -  Life expectancy of at least 12 weeks from the first dose of study treatment)\n        Randomized Part\n        Subjects eligible for enrollment in the Randomized Part of the study must meet all of the\n        following criteria:\n          -  Signed informed consent\n          -  Male or female; \u2265 20 years (at the time of giving consent)\n          -  Histologically or cytologically confirmed gastric carcinoma with documented\n             amplification of ErbB2 by fluorescence in situ hybridization (FISH) in primary or\n             metastatic tumor tissue\n          -  Subjects who received one prior regimen for gastric carcinoma and defined as\n             progression disease. The regimen must be containing 5-fluoropyrimidine and/or\n             cisplatin\n          -  Measurable lesion(s) according to RECIST (Response Evaluation Criteria in Solid\n             Tumors)\n          -  Left ventricular ejection fraction (LVEF) within institutional range of normal as\n             measured by echocardiogram. MUGA scans will be accepted in cases where an\n             echocardiogram cannot be performed or is inconclusive (LVEF of \u226550% required if\n             normal range of LVEF is not provided by institution)\n          -  ECOG Performance Status of 0 to 1\n          -  Able to swallow and retain oral medication\n          -  Archived (or Biopsy ) tumor tissue available for FISH testing [Wolff, 2007] in\n             central laboratory\n          -  Women and men with potential to have children must be willing to practice acceptable\n             methods of birth control during the study\n          -  Washout period from the prior last therapy as follows; Chemotherapy (except for\n             agents below) 4 weeks (IV) Chemotherapy (except for agents below) 2 weeks (P.O)\n             Trastuzumab, Bevacizumab 4 weeks Mitomycin-C, nitrosourea 6 weeks Radiotherapy,\n             Immunotherapy, Biologic therapy and Surgery (except for minor surgical procedure) 2\n             weeks\n          -  Willing to complete all screening assessments as outlined in the protocol\n          -  Adequate organ function as defined in Table 2\n          -  Gastrectomy status depending on the result in the Pilot Part\n          -  Life expectancy of at least 12 weeks from the first dose of study treatment\n        Table 2 Baseline Laboratory Values\n        SYSTEM LABORATORY (VALUES)\n        Hematologic:\n        ANC (absolute neutrophil count)\n        Hemoglobin:\n        Platelets (\u2265 2.0 \u00d7 10^9/L) (\u2265 9 g/dL) (\u2265 100 \u00d7 10^9/L) Hepatic Albumin Serum bilirubin AST\n        and ALT (\u2265 2.5 g/dL) (\u2264 1.25 x ULN) (\u2264 2.5 \u00d7 ULN without liver metastases) (\u2264 5 \u00d7 ULN if\n        documented liver metastases) Renal Serum Creatinine\n        Calculate Creatinine Clearance (see Section 11.3) (\u2264 2.0 mg/dL)\n        - OR - (\u226530 mL/min)\n        Exclusion criteria:\n        Subjects meeting any of the following criteria must not be enrolled in the study:\n          -  Pregnant or lactating female at anytime during the study\n          -  Planned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy,\n             biologic therapy, hormonal therapy) while taking investigational treatment\n          -  Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities\n             greater than grade 2)\n          -  Peripheral neuropathy of Grade 2 or greater\n          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function.\n             Subjects with ulcerative colitis and Crohn's disease are also excluded\n          -  History of other malignancy. However, subjects who have been disease-free for 5\n             years, or subjects with a history of completely resected non-melanoma skin cancer or\n             successfully treated in situ carcinoma, are eligible\n          -  Concurrent disease or condition that would make the subject inappropriate for study\n             participation or any serious medical disorder that would interfere with the subject's\n             safety\n          -  Life threatening infection\n          -  Dementia, altered mental status, or any psychiatric condition that would prohibit the\n             understanding or rendering of informed consent\n          -  Known history of uncontrolled or symptomatic angina, arrhythmias, or congestive heart\n             failure\n          -  Known history or clinical evidence of central nervous system (CNS) metastasis\n          -  Concurrent treatment with prohibited medications, including herbal remedies and\n             Chinese traditional medicines\n          -  Concurrent treatment with an investigational agent within 28 days prior to the\n             administration of paclitaxel and/or lapatinib\n          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs\n             chemically related to paclitaxel, including polyethoxylated castor oil, alcohol, or\n             lapatinib or their excipients\n          -  Anamnesis or diagnosis of pulmonary disorder, such as interstitial pneumonia,\n             pulmonary fibrosis or serious hypoxia\n          -  Gastrectomy surgery if Pilot Part of the study determines that partial gastrectomy\n             (pylorus spared) or total/partial gastrectomy (pylorus removed) has a significant\n             negative impact upon lapatinib PK and safety profile\n          -  Known history of use of any EGFR agent (except Trastuzumab)\n          -  Prior gastric cancer treatment which included a taxane.\n", "cuis": "C0024623 C0699791 C1880913 C1880914 C1880920 C1880921 C1880928 C1880929 C3811910 C3539181 C3539182 C3539954 C3539955 C3539956 C3539957 C3539959 C3539960 C3539961 C3539962 C3539963 C3539964 C3539965 C3539966 C3539967 C3539968 C3539969 C3539970 C3539971 C3539972 C3539973 C3539974 C3539975 C3539976 C3539977 C3539978 C3539979 C3540026 C3540027 C3540028 C3540030 C3540031 C3540719 C3540720 C3540721 C3540722 C3540723 C3540724 C3540740 C3854036 C0144576 C1506770 C2346836 C1550655 C1578485 C1578486 C2360836 C2360838 C2360840 C0725066 C1706099 C1552616 C1706244 C0947630 C3897779 C0144576 C1506770 C2346836 C3244317 C3897779 C0144576 C1506770 C2346836 C0220825 C2065082 C0144576 C0243161 C0013893 C0243161 C0877248 C1963761 C1561528 C1301624 C1547316 C3714732 C1552740 C3245491 C1552578 C0013230 C0220825 C1261322 C1550530 C0030258 C0013893 C3899561 C1555587 C3888021 C1516879 C0947630 C0243161 C1519316 C0009797 C0699791 C0349529 C1299583 C0599749 C0011546 C0439857 C0027651 C3842359 C2349568 C0699791 C0349529 C0040808 C2945654 C2363670 C0242656 C1141957 C1854494 C1834700 C1947900 C0049188 C0596581 C0393034 C1458156 C2825055 C0040808 C2945654 C0008838 C0671450 C0428772 C0042508 C0488728 C1736907 C2733342 C0428781 C1096403 C2114363 C3248440 C0801092 C2114366 C0860560 C1553386 C2702329 C0562359 C0013516 C2243117 C0183129 C2022421 C2022422 C2040661 C2022577 C2022578 C0441633 C0013516 C2243117 C0183129 C2022421 C2022422 C2040661 C2022577 C2022578 C3266744 C3245501 C3245502 C1619636 C1553386 C1546848 C2702329 C1555587 C1518965 C1518966 C2346639 C1518967 C1518968 C2346640 C2346642 C2346643 C2346644 C2346645 C2346646 C2346647 C2346648 C2346649 C2346641 C1520224 C1831741 C0027651 C1555459 C2712086 C4048182 C0566359 C0175795 C0237607 C3245512 C0600109 C0558080 C2222792 C0700589 C2703065 C0025663 C0025664 C0947630 C0013216 C0392920 C3665472 C0805598 C3845185 C0087111 C0033972 C0025344 C0013216 C0392920 C3665472 C0805598 C3845185 C1522449 C0034619 C1384668 C0419093 C0728747 C0796392 C4054033 C0002475 C0026254 C0028210 C3540781 C0543467 C1391251 C3846422 C0026035 C0038904 C0524850 C0524861 C3874032 C0021083 C0087111 C0033972 C1705196 C3842534 C3842535 C3842536 C1446899 C0005522 C1548762 C3272559 C1261322 C0031809 C0220825 C0870300 C0199230 C0220908 C1409616 C1698960 C1710031 C0442711 C1507394 C1522729 C2348563 C3715209 C0600109 C1815293 C0022885 C1571737 C2598148 C0031843 C1705273 C0178784 C1706074 C1554112 C0728774 C0701159 C1299581 C0056685 C0002778 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0947630 C3897779 C3888021 C1516879 C0947630 C3897779 C0243161 C1519316 C0009797 C0699791 C0349529 C1301725 C1609436 C1301746 C1547673 C1563337 C1300517 C2368153 C0303920 C0544711 C0027627 C0220650 C0699791 C0349529 C0040808 C2945654 C0049188 C0596581 C0393034 C0242656 C0012634 C0018609 C0040808 C2945654 C0008838 C0671450 C0935549 C1704632 C1706817 C2911692 C0027651 C1578706 C3273930 C0428772 C0042508 C0488728 C1736907 C2733342 C0428781 C1096403 C2114363 C3248440 C0801092 C2114366 C0860560 C1553386 C2702329 C0562359 C0013516 C2243117 C0183129 C2022421 C2022422 C2040661 C2022577 C2022578 C0441633 C0013516 C2243117 C0183129 C2022421 C2022422 C2040661 C2022577 C2022578 C3245501 C3245502 C1619636 C3266744 C1553386 C1546848 C2702329 C1555587 C1520224 C3830341 C3830342 C3830343 C3830344 C3830345 C3830346 C1518965 C2712086 C4048182 C0566359 C0175795 C0392366 C0809418 C0871472 C0005558 C1546569 C1548825 C1706430 C3668914 C0027651 C3827283 C0445420 C0022885 C1571737 C2598148 C0237607 C3245512 C0600109 C0558080 C2222792 C0700589 C2703065 C0025663 C0025664 C0947630 C0013216 C0392920 C3665472 C0805598 C3845185 C0087111 C0033972 C0025344 C0013216 C0392920 C3665472 C0805598 C3845185 C1522449 C0034619 C1384668 C0419093 C0728747 C0796392 C4054033 C0002475 C0026254 C0028210 C3540781 C0543467 C1391251 C3846422 C0026035 C0038904 C0524850 C0524861 C3874032 C0021083 C0087111 C0033972 C1705196 C3842534 C3842535 C3842536 C1446899 C0005522 C1548762 C3272559 C1261322 C0031809 C0220825 C0870300 C0199230 C0220908 C1409616 C1698960 C1710031 C0442711 C1507394 C1522729 C2348563 C3715209 C0600109 C1815293 C0031843 C1705273 C0178784 C1706074 C0017118 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0947630 C0022885 C1571737 C2598148 C1706074 C1554112 C0728774 C0022885 C1571737 C2598148 C0200627 C1547985 C0948762 C0518015 C1561562 C2239101 C0200695 C1281911 C1275423 C1168037 C3161174 C0948093 C3888302 C2984939 C0002895 C0474543 C0428441 C0032181 C1963076 C0205054 C0201838 C0591050 C0494165 C0494165 C0201976 C2981751 C4055609 C1301725 C1609436 C1301746 C1547673 C1563337 C0022646 C0042075 C0373595 C0812399 C1551341 C0007876 C1443182 C0243161 C0243161 C0947630 C0549206 C0947630 C2828358 C3668831 C0920425 C0021083 C0392920 C3665472 C0013216 C0580690 C0013218 C2717829 C0034619 C1384668 C1522449 C0279025 C3245491 C1552578 C0013230 C0220825 C1261322 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0033972 C0920425 C0600688 C0443343 C3714811 C0687696 C0031117 C4069195 C1263857 C1697744 C4013966 C0441802 C0475270 C1513374 C0024523 C0276457 C0031843 C1705273 C0012634 C0018609 C2707256 C0596601 C0809794 C0017173 C0184122 C0687713 C0920703 C0017181 C0017185 C0203054 C0237938 C0436865 C0744333 C0849766 C1141929 C2697368 C0009324 C0559166 C0348737 C1260710 C0574097 C0010346 C0455419 C1552867 C0006826 C1306459 C3842363 C0262926 C2004062 C0012634 C0018609 C0151779 C0699893 C0015252 C0262926 C2004062 C0007097 C0332155 C0012634 C3864998 C0009647 C0871117 C0018609 C0947630 C0021141 C0012634 C0009450 C3714514 C0275524 C0012683 C0035637 C0276041 C0729555 C0747002 C0278061 C3842026 C0012634 C3864998 C0009647 C0871117 C0497327 C0011265 C0138547 C0084178 C1548428 C3526598 C0162340 C0009797 C0003811 C0262926 C2004062 C0002962 C2024883 C0018787 C0231221 C0027627 C2939420 C2939419 C1328685 C0262926 C2004062 C0027769 C3272565 C0013227 C2094204 C0802604 C2598133 C2081612 C0033045 C0138547 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C0920324 C1515884 C0013230 C0087111 C3887704 C0376495 C1533734 C0746919 C0814472 C3647788 C1533734 C0376495 C0199808 C0199810 C0725057 C1536282 C0001563 C0036589 C0150270 C3469597 C0144576 C1506770 C2346836 C0020522 C0020517 C0231191 C1697779 C0013227 C0071558 C0144576 C0001962 C0001975 C0233492 C0445356 C1506770 C2346836 C0206061 C0085786 C1800706 C1279945 C0032298 C3686944 C0221236 C0024115 C0011900 C0945731 C0551521 C0552426 C0560182 C0686906 C0679838 C0034069 C0242184 C0030600 C2237940 C0029701 C0399711 C3714531 C0017118 C0543467 C1457907 C2081627 C0947630 C0030600 C2237940 C0029701 C0399711 C3714531 C0034196 C1506770 C2346836 C1513916 C0728747 C0262926 C2004062 C0920425 C0038351 C0224155 C1304960 C0215136 ", "concepts": "Gastric Cancers, Gastric Cancer, pM0 Gastric Cancer, pM1 Gastric Cancer, pNX Gastric Cancer, pT0 Gastric Cancer, pTX Gastric Cancer, pTis Gastric Cancer, Combination, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, combinations, Paclitaxel, Lapatinib, apatinib, Patient, Patient, Patient, Patient, Patient, Patient, Advance, Amplifier summary, summary study, Randomiz paclitaxel, lapatinib, apatinib, given, Randomiz paclitaxel, lapatinib, apatinib, Evaluate, coveralls paclitaxel criteria, Eligibility criteria adverse events, No adverse event, Information, contraindication, Contraindication, Contraindication, specific investigational, investigation, investigational drug, Investigation, Investigation, has pertinent information Brochure, Eligibility, Investigator CVs, provider enrollment, Enrollment, study criteria Signed, informed consent form gastric carcinoma, gastric carcinoid, independent, independency, dependency, dependence, tumor, Other malignancy confirmed histologicaly or cytologically, AIN I and II (histologically confirmed) gastric carcinoma, gastric carcinoid, regimen, regimen, developer Disease progression NOS, HIV disease progression, Slow disease progression, Rapid disease progression, Disease progression NOS, 5-fluoropyrimidine, fluoropyrimidine, 5-fluoropyrimidinone, recurrence, Recurrence, regimen, regimen cisplatin, ME cisplatin LVEF - Left ventricular ejection fraction, ventricular ejection fraction, Left ventricular Ejection fraction, left ventricular ejection fraction < 40%, Left ventricular ejection, Right ventricular ejection fraction, Left ventricular ejection fraction decreased, left ventricular ejection fraction assessment, Left ventricular ejection fraction (lvef) < 40%, Left ventricular Ejection fraction by US, left ventricular ejection fraction > or = 40%, Left ventricular ejection decreased, normal, Orange, institutionalized echocardiography, Echocardiogram, echocardiographs, echocardiogram SVC, echocardiogram IVC, echocardiogram VSD, echocardiogram LVOT, echocardiogram RVOT, scans echocardiography, Echocardiogram, echocardiographs, echocardiogram SVC, echocardiogram IVC, echocardiogram VSD, echocardiogram LVOT, echocardiogram RVOT, Virus inconclusive required, required, Required, normal, Institution, Orange, provider Performance Status, Performance Status 0, Performance Status 0, Performance Status 1, Performance Status 5, Performance Status 10, Performance Status 20, Performance Status 30, Performance Status 40, Performance Status 50, Performance Status 60, Performance Status 70, Performance Status 80, Performance Status 90, Performance Status 100, ECOG1-Performance Status, Poor Performance Status, Oncology, Oncology Able to swallow, Unable to swallow, Able to swallow food, oral medication practices, practice, willing, Unwilling, OT potential birth controls, birth control, methods, methods, study Chemotherapy, chemotherapy, Chemotherapy NOS, Chemotherapy Rx, IV Chemotherapy, therapy, Cotherapy, period Chemotherapy, chemotherapy, Chemotherapy NOS, Chemotherapy Rx, IV Chemotherapy Radiotherapy NOS, radiotherapy, radiotherapy, Radiotherapy NEC, Trastuzumab, Bevacizumab, Sevacizumab, Mitomycin, Mitomycins, nitrosourea, Nitrosoureas Surgery, c.surgical procedure, No surgical procedure, Microsurgical procedure, Minor surgical procedure, neurosurgical procedures, surgical procedures oral, Surgical procedure kit, Immunotherapy, therapy, Cotherapy, Surgery, Surgery 3, Surgery 2, Surgery 1, minor, Biologics, Biological, Biological assessment, Assessment, Assessment, Assessment, screening, Screening, screening, screening, Screening, Protocol, Protocol, Protocol, Protocol, Protocol, Willing, Complete Laboratory, Laboratory, Laboratory, function, Function, organ, Table, Value, Vaseline hospitalized, Able, cyclen, Analysis Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, study Randomiz enrollment, Enrollment, study, Randomiz criteria Signed, informed consent form gastric carcinoma, gastric carcinoid, Documented, Documented, document, document, document Hybridization, HPV hybridization, fluorescent, Autofluorescence metastatic tumor, brain metastatic tumor gastric carcinoma, gastric carcinoid, regimen, regimen 5-fluoropyrimidine, fluoropyrimidine, 5-fluoropyrimidinone, progression, disease, h disease, regimen, regimen cisplatin, ME cisplatin Evaluation Criteria, response, Response, Response Tumor, Tumor, Tumor LVEF - Left ventricular ejection fraction, ventricular ejection fraction, Left ventricular Ejection fraction, left ventricular ejection fraction < 40%, Left ventricular ejection, Right ventricular ejection fraction, Left ventricular ejection fraction decreased, left ventricular ejection fraction assessment, Left ventricular ejection fraction (lvef) < 40%, Left ventricular Ejection fraction by US, left ventricular ejection fraction > or = 40%, Left ventricular ejection decreased, normal, Orange, institutionalized echocardiography, Echocardiogram, echocardiographs, echocardiogram SVC, echocardiogram IVC, echocardiogram VSD, echocardiogram LVOT, echocardiogram RVOT, scans echocardiography, Echocardiogram, echocardiographs, echocardiogram SVC, echocardiogram IVC, echocardiogram VSD, echocardiogram LVOT, echocardiogram RVOT, required, required, Required, Virus inconclusive normal, Institution, Orange, provider ECOG - Performance Status, ECOG Performance Status 5, ECOG Performance Status 4, ECOG Performance Status 3, ECOG Performance Status 2, ECOG Performance Status 1, ECOG Performance Status 0, Performance Status Able to swallow, Unable to swallow, Able to swallow food, oral medication testing, q testing, t testing, Biopsy, Biopsy, Biopsy, Biopsy, Biopsy, tumor, Archive, Wolffi Laboratory, Laboratory, Laboratory practices, practice, willing, Unwilling, OT potential birth controls, birth control, methods, methods, study Chemotherapy, chemotherapy, Chemotherapy NOS, Chemotherapy Rx, IV Chemotherapy, therapy, Cotherapy, period Chemotherapy, chemotherapy, Chemotherapy NOS, Chemotherapy Rx, IV Chemotherapy Radiotherapy NOS, radiotherapy, radiotherapy, Radiotherapy NEC, Trastuzumab, Bevacizumab, Sevacizumab, Mitomycin, Mitomycins, nitrosourea, Nitrosoureas Surgery, c.surgical procedure, No surgical procedure, Microsurgical procedure, Minor surgical procedure, neurosurgical procedures, surgical procedures oral, Surgical procedure kit, Immunotherapy, therapy, Cotherapy, Surgery, Surgery 3, Surgery 2, Surgery 1, minor, Biologics, Biological, Biological assessment, Assessment, Assessment, Assessment, screening, Screening, screening, screening, Screening, Protocol, Protocol, Protocol, Protocol, Protocol, Willing, Complete function, Function, organ, Table Gastrectomy Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, study Laboratory, Laboratory, Laboratory, Table, Value, Vaseline Laboratory, Laboratory, Laboratory Hematology, Hematology absolute neutrophil count hemoglobin, Hemoglobin, Hemoglobin, Hemoglobin F, Hemoglobin A, Hemoglobin C, Hemoglobin E, Hemoglobin H, Hemoglobin S, Hemoglobin S, Hemoglobin B, Hemoglobin SS, Hemoglobin A2 Serum bilirubin, platelets, Platelets, Hepatic, Albumin, Albuminar liver metastases liver metastases, Serum Creatinine, Serum Creatinine Assay, APCH1-Serum Creatinine, Documented, Documented, document, document, document, Renal, Renal Creatinine Clearance, Creatinine clearance, Section, C-Section, Calculated criteria criteria, study Pregnant, study, Lactating, Lactating cancer therapy, immunotherapy, Chemotherapy, Chemotherapy, Chemotherapy, TB chemotherapy, polychemotherapy, Polychemotherapy, radiotherapy, radiotherapy, radiotherapy therapy, hormonal, investigational, investigation, investigational drug, Investigation, Investigation, therapy, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, Cotherapy cancer treatment, toxicity, unstable, resolved grade 2 Peripheral neuropathy, NOS, Neuro: Peripheral neuropathy, Peripheral axonal neuropathy, HIV peripheral neuropathy, Peripheral neuropathy (rare), Grade 2, Grade 2, Grade 2 Malabsorption syndrome, Avian malabsorption syndrome, function, Function, disease, h disease, Gastrointestinal, gastrointestinal gas, gastrointestines, gastrointestinal agent, gastrointestinal tubes, gastrointestinal pains, gastrointestinal sign, gastrointestinal bleed, gastrointestinal tumor, X-ray gastrointestinal, Ulcer gastrointestinal, O/E - gastrointestinal, gastrointestinal polyp, gastrointestinal colic, edema gastrointestinal, Upset gastrointestinal ulcerative colitis, H/O: ulcerative colitis, Other ulcerative colitis, Acute ulcerative colitis, FH: Ulcerative colitis, Crohn's disease, NOS, FH: Crohn's disease, exclude malignancy, Malignancy, No malignancy, History, History, disease, h disease melanoma skin cancer, nonmelanoma skin cancer, resected, history, history carcinoma, untreated disease, Condition, conditioning, precondition, h disease, study, ADH inappropriate disorder Infection, infections, Coinfections, Disinfection, RP infection, MG infection, GI infection, op infection altered mental status, Medical-altered mental status, condition, Condition, conditioning, precondition, Dementias, dementia, prohibited, prohibitin, Psychiatric, Psychiatric understanding, informed consent form arrhythmias, history, history, anginas, angina, heart, Asymptomatic metastasize, metastasize, Metastasis, metastat, history, history, nervous, Clinical medications, medications:, Medications, Medications, medication:, Premedications, prohibited, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment, Remedies traditional Chinese medicine investigational agent, Treatment, treatment, Retreatment, Treatment, no treatment, co-treatment, maltreatment administration, Readministration, Dpt administration, Mmr administration, administration sets, Maladministrations, oral administration, self administration, Drug administration, drug administration, paclitaxel, lapatinib, apatinib delayed hypersensitivity, hypersensitivity reaction, idiosyncrasy, immediate, drugs polyethoxylated castor oil, paclitaxel, alcohol, alcohol, elated, Unrelated lapatinib, apatinib interstitial pneumonia, usual interstitial pneumonia, usual interstitial pneumonia, Acute interstitial pneumonia, Lipoid interstitial pneumonia, Bronchointerstitial pneumonia, Chronic interstitial pneumonia, pulmonary disorder, diagnosis, Diagnosis, ED diagnosis, ED diagnosis, no diagnosis, No diagnosis, Misdiagnosis pulmonary fibrosis, hypoxia Partial gastrectomy, partial gastrectomy, Other partial gastrectomy, Polya partial gastrectomy, distal partial gastrectomy, Gastrectomy, surgery, surgery, surgery:, study Partial gastrectomy, partial gastrectomy, Other partial gastrectomy, Polya partial gastrectomy, distal partial gastrectomy, pylorus lapatinib, apatinib, Negative Trastuzumab, history, history cancer treatment, gastric, digastric, Digastric, taxane "}
